We are live on ! Find out more
KTTA icon

Pasithea Therapeutics
KTTA

8 hedge funds and large institutions have $985K invested in Pasithea Therapeutics in 2022 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 2

14% more funds holding

Funds holding: 7 → 8 (+1)

0.03% more ownership

Funds ownership: 0.14% → 0.17% (+0.03%)

9% less capital invested

Capital invested by funds: $1.09M → $985K (-$101K)

Holders
8
Holders Change
+1
Holders Change %
+14.29%
% of All Funds
0.13%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
3
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$92.2K
2
MSFP
Mark Sheptoff Financial Planning
Connecticut
+$60.7K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$55.5K
4
TSS
Two Sigma Securities
New York
+$23.9K
5
BlackRock
BlackRock
New York
+$1.84K

Top Sellers

Rank Fund Capital Flow
1
TRCT
Tower Research Capital (TRC)
New York
-$52K
2
HF
HRT Financial
New York
-$22K

KTTA Hedge Fund Activity: Q1 2022 in Review

8 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Pasithea Therapeutics (KTTA) for Q1 2022, worth a combined $985K — down 9.3% from $1.09M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new KTTA positions and 2 closed out — a net gain of 1 holder — while 3 added to existing stakes and 0 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $92.2K. The largest seller was Tower Research Capital (TRC), exiting entirely with an estimated $52K sold.

  • 8 institutional investors held Pasithea Therapeutics (KTTA) as of Q1 2022, up from 7 in Q4 2021.
  • Funds reported $985K of Pasithea Therapeutics stock for Q1 2022, down 9.3% quarter-over-quarter.
  • 3 funds opened new Pasithea Therapeutics positions in Q1 2022 and 2 closed out, a net change of +1 holder.
  • The largest Pasithea Therapeutics buyer in Q1 2022 was Citadel Advisors, an estimated $92.2K added.
  • The largest Pasithea Therapeutics seller in Q1 2022 was Tower Research Capital (TRC), an estimated $52K sold.

Based on aggregated 13F filings for Q1 2022.